Psychedelic Therapy 2026: MDMA, Psilocybin, Phase III Trials, FDA and Status in Poland

Psychedelic therapy has evolved over the last decade from a scientific curiosity to a serious branch of psychiatry. Phase III studies by MAPS on MDMA in post-traumatic stress disorder (PTSD) showed that 71% of patients lost their PTSD diagnosis after 3 therapy sessions (Mitchell 2023, Nature Medicine, 2023). Goodwin 2022 in the New England Journal of Medicine demonstrated that a single dose of 25 mg of psilocybin reduces the MADRS scale in treatment-resistant depression by 12 points after 3 weeks. This is data that psychiatry hasn't seen since the 1950s.

This guide presents a complete picture, free from media exaggeration and scientific minimization. We will discuss the history of psychedelic therapy from Albert Hofmann, Stanislav Grof, and Timothy Leary to the Johns Hopkins renaissance, the mechanisms of action of MDMA and psilocybin, key phase II and III clinical studies, the FDA decision from August 2024 regarding Lykos Therapeutics, regulations in Oregon, Colorado, and Australia, safety profiles, and the legal status in Poland. For Polish readers, we will also present legal pathways for mental health support in 2026.

The article is based on peer-reviewed publications in the New England Journal of Medicine, JAMA Psychiatry, Nature Medicine, The Lancet Psychiatry, Journal of Psychopharmacology, Scientific Reports, as well as reports from the Multidisciplinary Association for Psychedelic Studies (MAPS), Johns Hopkins Center for Psychedelic and Consciousness Research, and Compass Pathways. The author is Michał Waluk, editor of the u Bucha blog. The article does not constitute medical advice and does not promote the use of controlled substances in Poland.

What is psychedelic therapy and where did it come from?

Psychedelic therapy (Psychedelic-Assisted Psychotherapy, PAP) is a structured clinical protocol that combines the administration of a psychoactive substance in a controlled environment with preparatory and integrative psychotherapy. The review by Reiff 2020 in the American Journal of Psychiatry defines PAP as an intervention requiring a minimum of 4-8 preparatory sessions and 2-4 integrative sessions around 1-3 dosing sessions (American Journal of Psychiatry, 2020). This is not about "taking substances"; it is a clinically organized process.

The roots of psychedelic therapy date back to 1943, when Albert Hofmann accidentally discovered the effects of LSD in the Sandoz laboratories in Basel. In the 1950s and 1960s, over 1000 peer-reviewed publications emerged on the therapeutic use of LSD and psilocybin in alcoholism, depression, anxiety, and psychological trauma. Grof, Pahnke, Leary, Osmond. These names form the foundation of the first wave of psychedelic psychiatry.

The first wave ended politically, not scientifically. Controversies surrounding Timothy Leary, recreational abuse in the 1960s counterculture, and the political reaction of Richard Nixon led to the Controlled Substances Act of 1970, which placed psilocybin, LSD, and other psychedelics in Schedule I in the USA. Similar legislation was adopted in Europe. Clinical research stagnated for over 30 years.

Albert Hofmann, Stanislav Grof, and the first wave of psychedelic psychiatry

Albert Hofmann, a Swiss chemist, synthesized LSD in 1938 in search of a circulatory drug and discovered its effects on April 16, 1943. Five years later, in 1958, the same team isolated psilocybin and psilocin from Psilocybe mexicana mushrooms provided by ethnobotanist R. Gordon Wasson. Sandoz conducted free distribution of LSD and psilocybin to research centers worldwide under the trade names Delysid and Indocybin for 15 years.

Stanislav Grof, a Czech psychiatrist who worked in the 1960s in Prague and later in the USA (Spring Grove, Maryland), conducted thousands of sessions of LSD-assisted therapy. His concepts of "holotropic states of consciousness" and "perinatal matrix" influenced the entire subsequent development of transpersonal psychiatry. Grof documented the clinical benefits of LSD in existential anxiety, neuroses, and addictions in over 4,000 documented sessions.

Walter Pahnke, a psychiatrist from Harvard, conducted the famous "Good Friday Experiment" in 1962: he administered psilocybin to theology students during a Good Friday service. 9 out of 10 participants reported a "mystical experience." A follow-up after 25 years (Doblin 1991) showed that the experience was described as "one of the most significant religious and spiritual experiences of life" by most participants. This is the first empirical data on the long-term significance of mystical experience.

The Leary controversy and the Controlled Substances Act

Timothy Leary and Richard Alpert led the Harvard Psilocybin Project from 1960 to 1962. Research on psilocybin in prisoners, students, and clergy was scientifically promising but methodologically insufficiently controlled. Leary increasingly linked research with public promotion of psychedelics ("turn on, tune in, drop out"), which led to both being expelled from Harvard in 1963 and widespread negative social backlash.

The political reaction was swift. The Controlled Substances Act of 1970 in the USA and the UN Convention on Psychotropic Substances of 1971 placed LSD, psilocybin, mescaline, and other psychedelics in the most restrictive schedule, defined as "having no accepted medical value and a high risk of addiction." The consequence was the closure of clinical research for nearly three decades. The first FDA-approved protocol after the hiatus began only in 1990 (Rick Strassman, DMT).

Renaissance: Johns Hopkins, Imperial College, NYU

The renaissance of clinical research began in 2006 at Johns Hopkins. Roland Griffiths and his team published a groundbreaking study on psilocybin in healthy volunteers in Psychopharmacology, showing that 67% of participants reported the experience as "one of the five most important in their lives" (Psychopharmacology, 2006). This publication broke a 30-year silence.

Simultaneously, at Imperial College London, Robin Carhart-Harris, a student of David Nutt, was developing a research program on psilocybin in depression. NYU, under the guidance of Stephen Ross, began studies on psilocybin in cancer patients with existential anxiety. MAPS (Multidisciplinary Association for Psychedelic Studies), founded in 1986 by Rick Doblin, consistently developed the MDMA-assisted therapy program for PTSD. These four centers shaped the modern landscape of psychedelic psychiatry.

Psychedelic therapy is a structured clinical protocol requiring a minimum of 4-8 preparatory sessions and 2-4 integrative sessions around 1-3 dosing sessions (American Journal of Psychiatry, 2020). Its roots date back to 1943 (Hofmann), and the renaissance began in 2006 at Johns Hopkins (Griffiths). Leading centers: Johns Hopkins, Imperial College London, NYU, MAPS.

How do MDMA and psilocybin work at the neurobiological level?

MDMA and psilocybin are two completely different pharmacological classes. MDMA is an entactogen-empatogen, acting by releasing serotonin from the SERT transporter, as well as dopamine and norepinephrine. Psilocybin is a classic psychedelic, a partial agonist of the 5-HT2A receptor. Liechti 2022 in Trends in Pharmacological Sciences summarizes that both mechanisms lead to increased neuroplasticity and BDNF expression, but through different pathways (Trends in Pharmacological Sciences, 2022). However, the clinical effect converges within a similar therapeutic window.

Why do two different substances produce similar effects in different disorders? The Carhart-Harris and Friber hypothesis "REBUS and the Anarchic Brain" (2019) suggests that all psychedelics reduce the rigidity of cortical priors, opening a window of plasticity in which entrenched patterns can be reworked. In this model, MDMA and psilocybin have different "entry points" into the system, but a common metabolic and plastic effect.

MDMA: 5-HT releaser, empatogen, emotional tolerance window

MDMA (3,4-methylenedioxymethamphetamine) primarily acts as a substrate for the SERT transporter, reversing its direction and releasing serotonin into the synapse. Simultaneously, it releases dopamine (DAT) and norepinephrine (NET), although to a lesser extent. The result is a massive flooding of the synapse with serotonin: within 60-90 minutes after a dose of 80-180 mg, 5-HT levels increase 5-10 times. Additionally, MDMA stimulates the release of oxytocin from the hypothalamus and prolactin from the pituitary.

Key to therapy is MDMA's action on the amygdala and the medial prefrontal cortex (mPFC). Carhart-Harris 2014 in fMRI showed that MDMA reduces amygdala reactivity to stressors by 20-30%, while maintaining a high level of verbal awareness and introspection. Clinically, this is known as the emotional tolerance window: the patient can experience a traumatic memory without overwhelming anxiety.

Mithoefer 2011 describes the mechanism as follows: "MDMA allows for the consolidation of traumatic memories in a state of reduced arousal. The release of oxytocin and serotonin enhances the therapeutic relationship and trust between the patient and therapists" (Journal of Psychopharmacology, 2011). This is the pharmacological foundation of the entire MDMA-PTSD protocol.

Psilocybin: 5-HT2A agonist, Default Mode Network, ego dissolution

Psilocybin is a prodrug. After ingestion, it is dephosphorylated to psilocin (4-OH-DMT), which acts as a partial agonist of the 5-HT2A receptor. These receptors are densely present in the pyramidal neurons of layer V of the prefrontal cortex, hippocampus, and medial parietal cortex. Their activation destabilizes the Default Mode Network (DMN), a neural network responsible for rumination, the "self" narrative, and autobiographical thinking.

Carhart-Harris 2017 in Scientific Reports demonstrated with fMRI that psilocybin reduces DMN coherence, which correlates with the phenomenological phenomenon of "ego dissolution" and a reduction in depressive rumination (Scientific Reports, 2017). For a depressed patient whose mind is trapped in a negative narrative, this "reset" is one of the proposed mechanisms of the therapeutic effect.

Neuroplasticity BDNF, Wnt, dendritic spines

Both mechanisms converge on neuroplasticity. Shao 2021 in Neuron showed in animal models that a single dose of psilocybin increases dendritic spine density by 10% in layer V of the prefrontal cortex and raises BDNF levels for at least 30 days (Neuron, 2021). Ly 2018 previously showed a similar effect for LSD, DMT, and ketamine. MDMA, although it acts through a different receptor mechanism, also raises BDNF and Wnt/beta-catenin pathway activity.

This is the neurobiological basis for the "rapid-acting neuroplasticity" hypothesis. Typical SSRI antidepressants require 4-6 weeks to achieve a clinical effect, largely because their neuroplastic mechanism is indirect. Psychedelics directly stimulate synaptic plasticity through the activation of 5-HT2A or massive serotonin release, which explains the rapid onset of effect in RCTs (days, not weeks).

MDMA acts as a substrate for SERT, releasing serotonin, dopamine, norepinephrine, oxytocin, and prolactin; it reduces amygdala reactivity by 20-30% (Journal of Psychopharmacology, 2011). Psilocybin is a partial agonist of 5-HT2A, destabilizing the Default Mode Network (Scientific Reports, 2017). Both increase BDNF and dendritic spine density (Neuron, 2021).

What are the results of the MAPS phase III studies on MDMA in PTSD?

MAPS has been conducting the most consistent research program in psychedelic psychiatry for over three decades. Phase III studies include two parallel RCTs: MAPP1 (Mitchell 2021, Nature Medicine, n=90) and MAPP2 (Mitchell 2023, Nature Medicine, n=104). In both, 3 sessions of MDMA 80-180 mg plus 12 sessions of psychotherapy yielded statistically significant better outcomes than placebo plus the same therapy. In MAPP1, 67% of patients in the MDMA group lost their PTSD diagnosis after 18 weeks (Nature Medicine, 2021).

These results are indeed impressive in the context of PTSD, where standard pharmacotherapy (paroxetine, sertraline) achieves remission in 20-30% of patients after 12 weeks. PTSD has historically been one of the most challenging mental disorders to treat, especially in war veterans, survivors of sexual violence, and those with complex trauma. The clinical context explains why MAPS data has generated such immense hope and regulatory lobbying.

MAPP1 Mitchell 2021: 67% loss of PTSD diagnosis

MAPP1, published in Nature Medicine in May 2021, included 90 patients with severe PTSD (mean CAPS-5 score = 44, average duration of PTSD 15 years, 77% with at least one prior unsuccessful treatment). They were randomly assigned to two arms: MDMA 80-120 mg with two supplemental doses of 40-60 mg, plus 12 sessions of psychotherapy, or placebo plus identical psychotherapy. A total of 3 dosing sessions at intervals of 3-5 weeks.

Results of the primary endpoint (CAPS-5, Clinician-Administered PTSD Scale) after 18 weeks: a reduction of 24.4 points in the MDMA group vs 13.9 in the placebo group (p<0.0001, Cohen’s d = 0.91). 67% of MDMA patients no longer met the diagnostic criteria for PTSD vs 32% in the placebo group. 33% of the MDMA group achieved full remission (CAPS-5 ≤ 11) vs 5% in the placebo group. Safety: no serious cardiovascular events or suicidal enhancements.

MAPP2 Mitchell 2023: confirmation in moderate and severe PTSD

MAPP2, published in Nature Medicine in September 2023, expanded the trial to 104 patients with moderate and severe PTSD, including a more demographically and ethnically diverse group (Nature Medicine, 2023). Protocol: identical to MAPP1. Results: CAPS-5 reduction of 23.7 points in the MDMA group vs 14.8 in the placebo group (p<0.001, Cohen's d = 0.7).

71.2% of patients in the MDMA group no longer met PTSD criteria after 18 weeks compared to 47.6% in the placebo group. 46.2% of the MDMA group achieved full remission versus 21.4% in the placebo group. Safety profile: the most common adverse events were musculoskeletal stiffness (63%), nausea (41%), decreased appetite (34%), sweating (33%). 5 patients (4.8%) reported transient suicidal thoughts, with no completed attempts.

Follow-up: durability of the effect after 6 and 12 months

Jerome 2020 in Psychopharmacology described the long-term follow-up of the MAPS phase II studies (n=107): 12 months after the last MDMA session, 61% of patients still did not meet PTSD criteria, and 68% maintained clinically significant improvement (Psychopharmacology, 2020). Compared to typical antidepressants, where the effect often fades without continuous pharmacotherapy, this data on durability is of an entirely different order.

Importantly, all MAPS phase III patients were informed about the possibility of receiving MDMA after the study ended (open-label extension). This is an important methodological detail: the expectation of access to MDMA in the placebo group may have influenced reporting, which later became one of the FDA's arguments in the 2024 CRL.

MAPP2 (Mitchell 2023, n=104) showed a loss of PTSD diagnosis in 71% of the MDMA group versus 48% in the placebo with psychotherapy after 18 weeks (Nature Medicine, 2023). MAPP1 (Mitchell 2021, n=90) showed 67% vs 32%. The effect persisted for 12 months in 61% of patients in the phase II follow-up. Cohen's d = 0.7-0.91, which is an effect size 2-3 times greater than for SSRIs in PTSD.

Why did the FDA refuse to register MDMA in August 2024?

The FDA's decision on August 9, 2024, was a shock to the entire psychedelic psychiatry community. The FDA issued a Complete Response Letter to Lykos Therapeutics (the operational arm of MAPS) refusing to register midomafetamine (MDMA) for PTSD therapy. The agency requested an additional phase III study and responses to numerous methodological and safety issues (FDA, 2024). This effectively halts registration for 3-5 years.

The refusal was based on the recommendation of the Psychopharmacologic Drugs Advisory Committee (PDAC), which voted 9:2 against the efficacy of MDMA in PTSD and 10:1 against a favorable risk-benefit profile on June 4, 2024. This was a surprising vote, as just a few weeks earlier, most analysts expected a positive verdict. The FDA rarely rejects the recommendations of its advisory committees.

Methodological issues: blinding and confirmation bias

The first FDA objection concerned the inability to blind trials with MDMA. Patients receiving MDMA almost always know they received the active substance (MDMA has strong, distinct subjective effects). This phenomenon is known as "functional unblinding" and leads to reporting bias: patients aware of receiving MDMA more often report improvement. The FDA indicated that without true blinding of results, they cannot be accepted as definitive.

The second issue was participant selection. About 40% of individuals in the MAPS trials had prior experience with MDMA (recreational). This suggests a positive attitude towards the substance, which further strengthens expectation bias. The FDA highlighted the need to recruit psychedelic-naive patients and better placebo controls.

Reporting of adverse events and ethical controversies

The third and most painful accusation concerned the reporting of adverse events. In several MAPS centers, cases of inappropriate relationships between therapists and patients were reported, including one documented case of sexual contact between a therapist and a patient after a session (a center in Canada). MAPS acknowledged this situation, but the FDA deemed the reporting incomplete and systemic.

Additionally, the PDAC expressed concern about the reporting of suicidal thoughts and attempts. In MAPP2, an increase in suicidal thoughts was observed in 4.8% of patients in the MDMA group. The FDA concluded that the reporting protocol required improvement and more systematic long-term safety tracking.

What's next? The next phase III trial and registration horizon

Lykos Therapeutics announced plans to conduct an additional phase III study with improved blinding and safety monitoring procedures. A realistic FDA registration horizon: 2027-2029. In the meantime, MDMA remains in Schedule I in the USA and can only be used in registered research programs.

Some analysts, including PDAC members, indicated that the decision may be scientifically appropriate (blinding is a real issue), but it poses a significant challenge for psychedelic psychiatry. Without FDA registration, there will be no reimbursement programs, and the therapy costs of $15,000-30,000 are a barrier to access for most patients. This is a systemic issue, not just a regulatory one.

Unique observation: The FDA's decision from August 2024 reveals a fundamental tension in psychedelic therapy. On one hand, we have strong clinical effects (Cohen's d = 0.7-0.9), and on the other, the inability to achieve rigorous blinding. This is a structural problem, not a methodological one: if a substance has clear, subjective effects, no placebo will be truly blind. This raises the question of whether the standard FDA criteria for antidepressants even apply to psychedelics, or if psychiatry needs a new regulatory framework. This debate will continue for the next decade.

On August 9, 2024, the FDA refused to register MDMA (Complete Response Letter for Lykos Therapeutics), demanding an additional phase III study (FDA, 2024). The PDAC voted 9:2 against efficacy and 10:1 against a favorable risk-benefit profile. Major concerns: functional unblinding, confirmation bias, reporting of adverse events, cases of inappropriate therapist-patient relationships. The registration horizon has been pushed to 2027-2029.

What are the key studies on psilocybin in treatment-resistant depression?

Research on psilocybin in treatment-resistant depression (TRD) is currently the most densely populated data field in psychedelic psychiatry. A meta-analysis by Leger 2022 in the Journal of Psychopharmacology included 7 RCTs with a total of 436 patients and showed an average reduction in the Beck Depression Inventory scale of 12.2 points after 1-2 sessions of 20-25 mg of psilocybin, compared to 5.1 in the control group (Journal of Psychopharmacology, 2022). Cohen's d = 1.2-1.8, which is 3-4 times greater than the typical SSRI effect.

This picture is consistent across centers: Imperial College London, Johns Hopkins, University of Zurich, Compass Pathways in 10 countries. The replicability of the data is exceptional when compared to typical antidepressant studies, where effects are often inconsistent and disappear in large RCTs. Psilocybin has withstood every trial expansion so far.

Carhart-Harris 2021 Nature Medicine: head-to-head with escitalopram

The study by Robin Carhart-Harris from Imperial College London, published in Nature Medicine in April 2021, was the first head-to-head RCT comparing psilocybin with SSRIs (Nature Medicine, 2021). 59 patients with moderate to severe depression were randomly assigned to two arms: psilocybin 25 mg in session 1 and week 3 (with placebo escitalopram), or escitalopram 10-20 mg daily for 6 weeks (with placebo psilocybin 1 mg).

The primary endpoint (QIDS-SR-16) showed a reduction of 8.0 points in the psilocybin group vs 6.0 in the escitalopram group. The difference of -2.0 did not reach statistical significance (p=0.17), but psilocybin outperformed escitalopram in 14 out of 16 secondary endpoints, including well-being, anxiety, anhedonia, and sexual function. Remission was achieved by 57% of psilocybin patients vs 28% in the SSRI group. Two psychedelic sessions produced effects at least equivalent to 6 weeks of pharmacotherapy.

Goodwin 2022 NEJM: COMP360 in treatment-resistant depression

The phase IIb study by Compass Pathways (COMP360), published in the New England Journal of Medicine in November 2022, is the largest RCT of psilocybin in treatment-resistant depression (NEJM, 2022). Guy Goodwin from Oxford led a multicenter study across 10 countries, with 233 patients who had at least 2 failed attempts with antidepressants.

Three groups: psilocybin 25 mg, 10 mg, or 1 mg (active placebo), single session with psychotherapy. MADRS after 3 weeks: reduction of 12.0 points (25 mg), 7.9 (10 mg), 5.4 (1 mg). The difference between 25 mg vs 1 mg is statistically significant (p<0.001). Remission after 3 weeks was achieved by 29% of patients in the 25 mg group vs 8% in the 1 mg group. After 12 weeks, remission was maintained in 20% of patients in the 25 mg group.

Davis 2020 JAMA Psychiatry: Johns Hopkins, 71% clinical response

Alan Davis and Roland Griffiths' team at Johns Hopkins published in JAMA Psychiatry in November 2020 an RCT of psilocybin in non-resistant depression (MDD, n=27) (JAMA Psychiatry, 2020). Protocol: 2 sessions of 20-30 mg psilocybin with a total of 11 hours of psychotherapy. Immediate vs delayed treatment group (waiting list).

Reduction in GRID-HAMD averaged 17 points after 8 weeks, with 71% of patients achieving a clinical response (>50% reduction), and 54% achieving remission. Gukasyan 2022 in the Journal of Psychopharmacology showed in follow-up that the effect was maintained in 75% of patients for 12 months (Journal of Psychopharmacology, 2022). These are some of the most impressive data in psychiatry in the last decade.

New areas: oncological anxiety, OCD, anorexia, addictions

Griffiths 2016 (Johns Hopkins, n=51) and Ross 2016 (NYU, n=29) showed that a single session of psilocybin 22-30 mg reduces existential anxiety in over 60% of oncology patients (Journal of Psychopharmacology, 2016). Follow-up Agin-Liebes 2020 after 4.5 years: 60-80% of patients still benefited. This is an unprecedented result in palliative psychiatry.

Bogenschutz 2022 in JAMA Psychiatry (n=93) in alcohol use disorder (AUD): reduction of heavy drinking days by 83% vs 51% placebo after 32 weeks. Moreno 2006 in OCD and Johnson 2017 in nicotine addiction showed promising signals. Peck 2023 is starting an RCT of psilocybin in anorexia. Stiell in cluster migraine and Barrett in Alzheimer’s are developing further programs.

Key RCTs of psilocybin in depression: Carhart-Harris 2021 (Nature Medicine, n=59, 57% remission vs 28% escitalopram), Goodwin 2022 (NEJM, n=233, 29% remission after a single dose of 25 mg COMP360), Davis 2020 (JAMA Psychiatry, n=27, 71% clinical response at Johns Hopkins). Meta-analysis by Leger 2022 (7 RCTs, n=436): Cohen's d = 1.2-1.8, 3-4 times greater effect than SSRIs.

What are the regulatory frameworks in the USA, Australia, and Europe?

Regulations for psychedelic therapy in 2026 are fragmented and changing rapidly. Australia is the first country with registered substances (MDMA for PTSD and psilocybin for treatment-resistant depression from July 1, 2023, TGA Schedule 8). The USA granted Breakthrough Therapy status to MDMA (2017) and psilocybin (2018, 2019), but registration is delayed. Oregon and Colorado have implemented state therapeutic programs. Kuijken 2024 in The Lancet Psychiatry describes this landscape as "dispersed regulatory experimentation" (The Lancet Psychiatry, 2024).

For Europe, and particularly Poland, the horizon is further away. The EMA (European Medicines Agency) has not yet registered any psychedelic as a drug. Member countries have their own regulations, usually restrictive. Exceptions: Switzerland (special exception program since 2014) and the Netherlands (magic truffles as a gray area). For Polish patients in 2026, the only legal pathway is participation in RCTs conducted abroad.

FDA Breakthrough Therapy: MDMA 2017, psilocybin 2018 and 2019

The FDA granted MDMA Breakthrough Therapy Designation in August 2017 for PTSD therapy. This is an expedited registration pathway for drugs that "address an unmet medical need" with promising preliminary clinical data. Breakthrough status provides access to more frequent meetings with the FDA, rolling review of documentation, and priority review. Despite this, MDMA registration was rejected in August 2024.

Psilocybin received Breakthrough Therapy status twice: in October 2018 for Compass Pathways (COMP360 in treatment-resistant depression) and in November 2019 for Usona Institute (psilocybin in major depression, MDD). Both programs are ongoing, with phase III results expected in 2026-2027. FDA potential registration of psilocybin in treatment-resistant depression: horizon 2027-2028.

Oregon Measure 109 and Colorado Proposition 122: state programs

Oregon became the first U.S. state to legalize controlled psilocybin therapy in November 2020. Measure 109 established the Oregon Psilocybin Services Program (OPS), which since January 2023 authorizes service centers, facilitators, and clinics. By 2024, about 30 centers and 500 facilitators who completed a 120-hour training program have been registered (Oregon Health Authority, 2024).

Colorado passed Proposition 122 (Natural Medicine Health Act) in November 2022, which legalizes personal possession of psilocybin, DMT, mescaline, and ibogaine. Starting in 2025, the state will introduce therapeutic programs similar to Oregon's. A key difference: Colorado allows for "ceremonial use" outside of a medical context, while Oregon has focused on therapy. Both programs are experimental and monitored by the federal FDA.

Australia TGA 2023: the first country with MDMA and psilocybin by prescription

The Australian Therapeutic Goods Administration made an unprecedented decision in February 2023, moving MDMA and psilocybin from Schedule 9 (prohibited) to Schedule 8 (controlled prescription drugs) for PTSD (MDMA) and treatment-resistant depression (psilocybin). Since July 1, 2023, authorized psychiatrists can prescribe these substances (TGA Australia, 2023).

Authorization requires: specialized psychiatric training, protocol approval by an ethics committee, and unilateral written consent from the patient. The cost of a full cycle: 25,000-35,000 Australian dollars (approximately 65,000-90,000 Polish zlotys). By the end of 2024, about 50-70 authorized psychiatrists and several hundred completed therapies have been registered. This is a pioneering program, but with serious access limitations.

Europe: EMA, Switzerland, the Netherlands, and the UK

The EMA has not yet registered any psychedelic. Compass Pathways is conducting a phase III COMP360 multicenter program in the EU, with expected results in 2026-2027. Switzerland has had an exception program (Bundesamt für Gesundheit) since 2014, allowing selected psychiatrists to legally use LSD, psilocybin, and MDMA in individual cases. In 2023, about 70 such applications were accepted (BAG Switzerland, 2023).

The Netherlands maintains a gray area: psilocybin is illegal, but "magic truffles" (sclerotia of Psilocybe) are a legal product. Several retreat centers (Synthesis, Psyched2, Alalaho) offer therapeutic programs for foreigners for 1800-3500 euros. The UK has legalized medical ketamine, but psilocybin and MDMA remain Schedule 1. Research programs are ongoing at Imperial College and King's College London.

As of July 1, 2023, Australia is the first country to have MDMA for PTSD and psilocybin for treatment-resistant depression available by prescription (TGA Schedule 8) (TGA Australia, 2023). Oregon (Measure 109, 2020) and Colorado (Proposition 122, 2022) are running state psilocybin programs. The FDA denied MDMA in August 2024. Switzerland has had an exception program since 2014. EMA: no registration in 2026.

What are the protocols for therapeutic sessions with psychedelics?

The clinical protocol for a psychedelic session differs radically from "recreational" use. The Johns Hopkins Center for Psychedelic and Consciousness Research establishes a standard protocol: 4-8 preparatory sessions, 1-3 dosing sessions (6-8 hours each) with the presence of two therapists, 2-4 integration sessions. A total of 25-40 hours of clinical contact per patient (Johns Hopkins CPCR, 2021). The protocol is not optional.

Each element has a specific function. Preparation builds mindset (set), safety, and trust. Setting reduces the risk of a "challenging experience." The dosing session is the actual dosing under medical supervision. Integration translates fleeting insights into lasting behavioral change. Skipping any stage drastically increases the risk of traumatization and reduces the therapeutic effect.

Set: the patient's mindset, intention, "flight instructions"

Set encompasses everything the patient brings to the session: mood, expectations, fears, trauma history, health status. In the Johns Hopkins protocol, the set is built over 4-8 preparatory sessions lasting 60-90 minutes each. Topics discussed include: the patient's life narrative, trauma, therapeutic goals, concerns about the substance, therapeutic contract, and "flight instructions" (a set of rules for stabilizing during difficult moments).

Richards 2016 lists five principles of "flight instructions": "trust, let go, be open," plus breathing techniques and established nonverbal signals with therapists (handshake, touch on the shoulder). A patient entering a session without this preparation has a significantly higher risk of dysregulation and traumatization. Set is not esotericism; it is clinically validated prevention.

Setting: quiet room, eye mask, music, two therapists

Setting is the physical and interpersonal environment of the session. Johns Hopkins and MAPS recommend: a quiet room with warm lighting, a comfortable bed or chair, an eye mask, headphones with selected music (the standard Johns Hopkins playlist includes 6-8 hours of classical, ambient, sacred music), the presence of two therapists at all times, ensured sanitary breaks, monitoring of blood pressure and heart rate every 30-60 minutes.

Why two therapists? For transference dynamics (often one woman and one man), the possibility of complementary support, and the safety of the patient and therapist. In the MAPS protocol for PTSD, this principle is a prerequisite. The clinical setting differs radically from the recreational context, where the environment is unpredictable and support is random.

Integration: 2-4 psychotherapy sessions after dosing

Integration is the phase most often underestimated, yet crucial for the durability of the effect. It involves 2-4 psychotherapy sessions over 2-4 weeks after dosing. The goal is to translate mystical, emotional, and cognitive experiences into concrete changes in daily life, relationships, and habits. Without integration, even a strong psychedelic experience "fades away" within weeks.

Watts 2017 in the Journal of Humanistic Psychology showed in 20 patients with depression that those without structured integration were significantly more prone to symptom relapse within 6 months (Journal of Humanistic Psychology, 2017). Integration is not a luxury; it is part of treatment. For patients with PTSD and treatment-resistant depression, the lack of integration negates most of the session's effect.

Differences in the MDMA-PTSD vs psilocybin-depression protocol

The MAPS protocol for MDMA-PTSD: 3 eight-hour sessions with a dose of 80-180 mg at intervals of 3-5 weeks, plus 12 90-minute psychotherapy sessions. The patient lies down, and therapists conduct structured trauma work. MDMA reduces anxiety, allowing the patient to process traumatic memories within the window of emotional tolerance.

The Johns Hopkins protocol and COMP360 for psilocybin-depression: 4-8 preparatory sessions, 1-2 six-hour dosing sessions with a dose of 20-25 mg, 2-4 integration sessions. The patient lies down with an eye mask and headphones, listening to classical music. Therapists are mainly "present," not actively conducting verbal work. Psilocybin triggers a "mystical experience" that the patient processes during integration.

The Johns Hopkins protocol: 4-8 preparatory sessions, 1-3 dosing sessions lasting 6-8 hours with two therapists, 2-4 integration sessions, totaling 25-40 hours of clinical contact (Johns Hopkins CPCR, 2021). MAPS for MDMA-PTSD: 3 dosing sessions lasting 8 hours, 12 psychotherapy sessions. Integration critically affects the durability of the effect (Journal of Humanistic Psychology, 2017).

What are the most serious risks of psychedelic therapy?

Psychedelic therapy is not safe for everyone. Johnson 2019 in ACS Pharmacology and Translational Science lists seven areas of risk: cardiovascular, psychiatric, drug interactions, neurological, long-term perceptual, behavioral, legal (ACS Pharmacology, 2019). None are marginal. Proper patient qualification requires psychiatric, cardiological, and pharmacological screening.

Both MDMA and psilocybin have relatively low acute toxicity: psilocybin has no documented lethal LD50 in humans, MDMA has a therapeutic margin of about 10-30 times between the therapeutic dose and potentially lethal dose. However, there are specific subgroups and combinations that drastically change the safety profile. For MDMA, risks of hyperthermia, hyponatremia, and cardiotoxicity arise.

Family history of psychosis and bipolar affective disorder

The most serious contraindication for both substances is a family or personal history of schizophrenia, schizoaffective disorder, or bipolar affective disorder. Psilocybin as a 5-HT2A agonist and MDMA as a massive serotoninergic agent can trigger the first psychotic episode in individuals with a genetic predisposition. The risk is difficult to estimate because most RCTs exclude these groups.

In the serial data from Johns Hopkins from 2000-2019, 2 cases of psychosis were reported out of approximately 1200 sessions. In clinical practice, standard protocols exclude patients with first-degree relatives with SCZ or CHAD. For CHAD, psilocybin and MDMA can trigger a manic or hypomanic episode. This is not "excessive caution"; it is a hard safety criterion.

Serotonin syndrome: SSRI, SNRI, MAOI

Combining psilocybin or MDMA with serotonin-enhancing medications (SSRI, SNRI, MAOI, tramadol, triptans, lithium, some opioids) can trigger serotonin syndrome: hyperthermia, seizures, muscle rigidity, tachycardia, and in severe cases, death. Johns Hopkins and Compass Pathways require discontinuation of SSRI/SNRI for 2-6 weeks before the session. Fluoxetine, with its long half-life, requires a longer washout (4-6 weeks) than sertraline or escitalopram (2-3 weeks).

MAOIs are an absolute contraindication. Combining MAOIs with MDMA is the most dangerous scenario in all of psychedelic psychiatry: it can trigger a hypertensive crisis and a potentially fatal serotonin syndrome. Historically, several documented recreational deaths have been associated with the unintentional combination of MDMA and MAOIs or MDMA and plants containing harmine (ayahuasca). Never combine.

Cardiovascular: blood pressure, heart rate, hyperthermia

Psilocybin raises blood pressure by 15-25% and heart rate by 10-20 beats per minute within 60-90 minutes after dosing. MDMA increases systolic blood pressure by 25-40 mmHg and heart rate by 20-30 beats, with effects lasting 3-5 hours. In healthy individuals, these values are safe; in patients with ischemic heart disease, heart failure, uncontrolled hypertension, or arrhythmias, the risk of cardiovascular events increases.

MDMA additionally disrupts thermoregulation. In conditions of high ambient temperature and physical activity (recreational club context), life-threatening hyperthermia, rhabdomyolysis, and kidney failure may occur. In clinical settings (cool room, rest, monitoring), the risk is significantly lower but not zero. MDMA can also cause hyponatremia due to increased ADH release and excessive water intake.

HPPD, "challenging experience" and long-term risks

HPPD (Hallucinogen Persisting Perception Disorder) is a chronically recurring visual perception disorder after the effects of a psychedelic have ended (trails, halos, afterimages). It occurs in less than 1% of users but can persist for years. The risk is higher in individuals with migraine with aura, anxiety disorders, and schizotypy.

Carbonaro 2016 in the Journal of Psychopharmacology: 39% of 1993 psilocybin mushroom users reported a "challenging experience" with intense fear or anxiety; for 11%, the experience was "among the 5 most difficult in life" (Journal of Psychopharmacology, 2016). In clinical settings with a protocol, the frequency of traumatic reactions dramatically decreases. 30-40% of participants have difficult moments during dosing, but in a clinical context, they are processed as part of the therapeutic process.

Main risks of psychedelic therapy: triggering psychosis in predisposed individuals (2 cases per 1200 sessions at Johns Hopkins), serotonin syndrome with SSRI/SNRI/MAOI (MAOIs are absolutely contraindicated), increased blood pressure and heart rate (MDMA 25-40 mmHg, psilocybin 15-25%), challenging experience in 30-40% of participants (Journal of Psychopharmacology, 2016). MDMA additionally: hyperthermia, hyponatremia, cardiotoxicity.

What are the legal options for mental health support in Poland?

For individuals struggling with PTSD, depression, or anxiety in Poland, where psychedelic therapy remains illegal, there is a set of legal and well-researched tools. Since 2022, the NFZ has been funding psychodynamic therapy, cognitive-behavioral therapy (CBT), EMDR, and humanistic therapy in Mental Health Clinics. Escitalopram, sertraline, paroxetine, and venlafaxine are first-line medications for depression and PTSD. For treatment-resistant depression, esketamine (Spravato) and off-label ketamine are available (EMA Spravato, 2019).

The second level of support is medical cannabis by prescription (Bedrocan, Tilray, Aurora), available in Poland since 2017. The third level consists of non-pharmaceutical supplements: CBD oil, CBG, adaptogens (Lion's Mane, Rhodiola, Ashwagandha). This is not clinical treatment for depression or PTSD, but legal support for symptoms of anxiety, sleep problems, and subclinical tension during and between psychotherapy sessions.

Psychotherapy: CBT, EMDR, ACT in PTSD and depression

Cognitive-behavioral therapy (CBT) and EMDR (Eye Movement Desensitization and Reprocessing) are recommended by NICE and APA as first-line treatments for PTSD. A meta-analysis by Cuijpers 2023 in The Lancet Psychiatry (257 RCTs, n=25000) showed an average reduction of 8.6 points on the Beck Depression Scale after 12-16 sessions of CBT, with effects lasting 12 months in 60% of patients (The Lancet Psychiatry, 2023). Cost in Poland: NFZ for free (with a waiting list of 3-9 months) or privately 150-300 PLN per session.

EMDR is comparable in many meta-analyses to MDMA-assisted therapy in terms of effect on PTSD, with lower risk and better access. ACT (Acceptance and Commitment Therapy) has solid evidence in depression, anxiety, and chronic pain. In Poland, practicing psychotherapists are certified by PTTPB (Polish Society for Cognitive and Behavioral Therapy) or PTPD. Learn more about PTSD in our guide.

Pharmacotherapy with SSRI, SNRI, and esketamine

SSRIs (escitalopram, sertraline, paroxetine) and SNRIs (venlafaxine, duloxetine) are first-line medications for moderate to severe depression and PTSD. The effect appears in 4-6 weeks, with remission after first-line treatment achieved by 30-40% of patients. This is a weaker signal than psychedelics in RCTs, but with a better-known safety profile and easier outpatient use. We discuss the safety of combining antidepressants with cannabinoids separately.

Esketamine (Spravato) in nasal form has been registered in the EU for treatment-resistant depression since 2019. It requires administration in a medical facility under supervision 2 hours after application. Remission after 4 weeks is achieved by 27% of patients vs 12% in placebo (Daly 2019, JAMA Psychiatry). Off-label ketamine (intravenous, intramuscular) is available in several Polish centers, with an antidepressant effect within 24-72 hours.

CBD and CBG: support for anxiety and sleep, not clinical treatment

CBD (cannabidiol) is a non-psychoactive cannabinoid from hemp, legal in Poland. Shannon 2019 in Permanente Journal (n=72) showed a 79% improvement in anxiety after 25-75 mg of CBD daily for 4 weeks (Permanente Journal, 2019). CBD does not treat clinical depression or PTSD, but it may reduce subclinical anxiety and improve sleep. WHO assesses CBD as safe with no potential for addiction.

For the Polish reader, a practical option is SOOL Broad Spectrum CBD oil 5% for 76 PLN, where 1 drop is about 2.5 mg of CBD. A sensible start is 5-10 mg in the evening for 2 weeks, then possibly increasing to 25-50 mg daily in divided doses. For individuals with higher tension and insomnia, a stronger version is available: SOOL Broad Spectrum CBD Oil 10% for 99 PLN, where 1 drop provides about 5 mg of CBD.

CBG (cannabigerol) has a different pharmacological profile: it acts on 5-HT1A and alpha-2 adrenergic receptors, reported as more "daytime", supporting attention. Cannova CBG oil 15% for 240 PLN it provides about 7.5 mg of CBG per drop. For those preferring a quicker onset of action, it is available in the form of vaporization Mars CBD 9% flower for 59 PLN, with a bioavailability of 30-40% when vaporized (without combustion).

Observation at u Bucha: In conversations with clients, we see that those seeking "natural alternatives" to antidepressants often combine two separate worlds: psychedelics and cannabinoids. CBD is not "psilocybin without the rights" or "MDMA for the poor". It has a different pharmacological mechanism (endocannabinoid, 5-HT1A, TRPV1) and a different clinical profile. It may support sleep and reduce tension, but it does not replace psychotherapy, SSRIs, or ketamine in clinical depression. The best effects are seen in clients who combine CBD with regular therapy, movement, and sleep hygiene.

Legal pathways for mental health support in Poland: CBT and EMDR (Beck's depression scale reduction by 8.6 points, The Lancet Psychiatry, 2023), SSRIs/SNRIs, esketamine Spravato in treatment-resistant depression (27% remission vs 12% placebo, EMA, 2019), medical cannabis by prescription, CBD 25-75 mg in anxiety (Permanente Journal, 2019). Key: psychiatric consultation before any treatment change.

What is the horizon for the development of psychedelic therapy from 2026 to 2030?

The coming years will be decisive. Compass Pathways is conducting phase III of COMP360 multicenter trials in the USA and EU, with an expected report in 2026-2027. Lykos Therapeutics plans an additional phase III study of MDMA-PTSD, with a registration horizon of 2028-2029. Usona Institute continues its psilocybin program in MDD. Cybin is developing short-term analogs (CYB003, 4 hours vs 6-8 of classic psilocybin). Over 1000 patients in phase III trials (Compass Pathways, 2024).

For global psychiatry, this means that psychedelics could enter the mainstream in selected countries (USA, Australia, Switzerland, Germany) within 3-7 years. For Poland, the horizon is further away. Restrictive laws, lack of clinical programs, and political conservatism push realistic changes to 2030-2035, unless there is an earlier EMA decision enforcing harmonization.

Phase III COMP360 and the registration horizon for psilocybin

COMP360 by Compass Pathways is the most advanced psilocybin registration program. Phase III includes two parallel RCTs: COMP005 and COMP006, totaling about 900 patients with treatment-resistant depression. Protocol: single dose of 25 mg, with a full set-setting-integration protocol. The first report is expected by the end of 2026, the second in 2027. FDA and EMA registration in an optimistic scenario: 2027-2028.

If COMP360 is registered, it will be the first registered psychedelic in FDA history (excluding esketamine, which is not a classic psychedelic). It will also be the first psilocybin in reimbursement programs. The cost of one session: 15,000-25,000 USD, raising questions about equal access, reimbursement, and the economics of public health systems.

New areas of research: OCD, anorexia, cluster headache, Alzheimer’s

Areas beyond PTSD and depression where research is ongoing: obsessive-compulsive disorder (OCD), anorexia nervosa, Alzheimer’s disease (early stage), cluster headache, demoralization of terminal patients. Moreno 2006 showed a signal in OCD, Peck 2023 is starting an RCT in anorexia (n=10 pilot). Stiell is developing a psilocybin program for cluster headaches.

Anorexia is a particularly important area, as it has one of the highest mortality rates in psychiatry (5-20%) and limited effectiveness of existing therapies. If psilocybin shows a signal, it will be important evidence for the concept of "rigid" behavioral and cognitive disorders. Barrett is developing a program for early Alzheimer's disease, hypothesizing that psilocybin-induced neuroplasticity may slow progression.

Poland: first academic RCT, Polish Psychedelic Society

The Polish Psychedelic Society (PTP) is a public benefit organization operating since 2014, bringing together psychiatrists, psychologists, scientists, and journalists (Polish Psychedelic Society, 2024). PTP conducts educational activities, translates scientific publications, and supports applicants for research approvals. In 2024-2025, the first academic applications for conducting psilocybin research in Poland appeared (Warsaw, Gdańsk, Wrocław).

The procedures are tedious: approval from the Minister of Health, Chief Pharmaceutical Inspector, Bioethics Committee, protocol approval by URPL. The realistic horizon for the first results from Poland: 2027-2030. Real clinical availability in Poland: 2030-2035. We write in detail about the Polish context in the psilocybin guide.

Horizon 2026-2030: phase III COMP360 (Compass Pathways, 2026-2027), possible FDA registration of psilocybin (2027-2028), additional MDMA study by Lykos Therapeutics (horizon 2028-2029). New areas: OCD, anorexia, cluster headache, Alzheimer’s. In Poland, realistic regulatory changes are not expected before 2030-2035. Over 1000 patients in phase III trials (Compass Pathways, 2024).

Summary: what should we know about psychedelic therapy in 2026?

Conclusions from the last two decades of research are consistent but require nuance. Firstly, MDMA therapy in PTSD and psilocybin in treatment-resistant depression have solid phase II and III clinical evidence: Mitchell 2021 and 2023 in Nature Medicine (71% loss of PTSD diagnosis), Goodwin 2022 in NEJM (29% remission in TRD after a single dose), Davis 2020 in JAMA Psychiatry (71% clinical response), Carhart-Harris 2021 in Nature Medicine (57% remission vs 28% escitalopram). These results are 2-3 times better than standard pharmacotherapy.

Secondly, psychedelic therapy is not a "magic pill". The effect critically depends on the set-setting-integration protocol with 4-8 preparatory sessions, 1-3 dosing sessions, and 2-4 integration sessions. Skipping any stage nullifies most of the effect and drastically increases the risk of traumatization. Self-administering MDMA or psilocybin without a protocol is not therapy; it's gambling.

Thirdly, the risks are real: triggering psychosis in individuals with a family history of SZ or BD, serotonin syndrome with SSRIs/SNRIs (MAOIs are an absolute contraindication, risk of death), increased blood pressure and heart rate (MDMA 25-40 mmHg, cardiovascular risk), hyperthermia and hyponatremia (MDMA), challenging experiences in 30-40% of participants, rare HPPD. Patient qualification requires psychiatric, cardiological, and pharmacological screening.

Fourthly, regulations are in motion. Australia (TGA) has registered MDMA and psilocybin by prescription since July 1, 2023, with a cost of 25,000-35,000 AUD per cycle. Oregon and Colorado have state programs in the USA. The FDA denied registration of MDMA in August 2024, pushing the horizon to 2028-2029. Psilocybin registration (COMP360) is expected in 2027-2028. EMA still has no decision. Switzerland has had an exception program since 2014.

Fifthly, in Poland in 2026, MDMA and psilocybin remain illegal (Schedule I-P, penalties up to 10 years in prison). Registered therapeutic programs do not exist. The first Polish academic RCTs may appear in 2027-2030. Real clinical availability: 2030-2035. For a Polish patient with PTSD or depression today, the legal pathways are: CBT and EMDR psychotherapy, SSRI and SNRI pharmacotherapy, esketamine in treatment-resistant depression, medical marijuana by prescription, and additionally CBD and CBG in low doses.

Practical recommendation: if you are struggling with PTSD, depression, or anxiety, start with a psychiatric consultation. In PTSD, consider EMDR as a first-line treatment. In depression, CBT and SSRIs are the recommended starting point. In treatment-resistant depression, it is worth discussing esketamine or off-label ketamine. CBD and CBG can be a somatic supplement, not a substitute for clinical treatment. Keep an eye on research into psilocybin and MDMA, as the prospect of registration is approaching, though not yet in Poland.

Psychedelics are one of the most promising directions in psychiatry over the last decade, but they will not solve the systemic mental health issues in Poland: the shortage of psychiatrists, long queues at the NFZ, low availability of psychotherapy, and lack of resources for transgenerational trauma. Real progress requires multifaceted work: legislative, clinical, educational, and systemic. MDMA and psilocybin can be part of the solution, but they are not the whole picture.

Frequently Asked Questions

Are MDMA and psilocybin legal in Poland in 2026?

No. Both MDMA and psilocybin, as well as psilocin, are listed in Schedule I-P of the Act on Counteracting Drug Addiction from July 29, 2005 (Journal of Laws 2005 No. 179 item 1485). Their possession, production, trade, and cultivation of psilocybin mushrooms are crimes punishable by up to 10 years in prison. In 2026, there is no registered MDMA or psilocybin-assisted therapy program in Poland, apart from very limited scientific projects requiring approval from the Minister of Health, GIF, and the Bioethics Committee.

What did the FDA decide regarding MDMA-assisted therapy in August 2024?

In August 2024, the FDA issued a Complete Response Letter for the application from Lykos Therapeutics (formerly MAPS PBC) for the registration of midomafetamine (MDMA) in PTSD therapy. The FDA did not register the drug, citing issues with trial blinding, adverse event reporting, potential cases of improper therapist-patient relationship, and doubts about the generalizability of the results. The agency requested additional Phase III studies. This impacted the entire psychedelic therapy ecosystem and delayed registration by at least 3-5 years.

What are the results of the MAPS phase III studies on MDMA in PTSD?

MAPP1 (Mitchell 2021, Nature Medicine, n=90) showed that 3 sessions of MDMA 80-180 mg led to the loss of PTSD diagnosis in 67% of patients with severe PTSD compared to 32% in the psychotherapy with placebo group after 18 weeks (Nature Medicine, 2021). MAPP2 (Mitchell 2023, Nature Medicine, n=104) confirmed the result in patients with moderate and severe PTSD: 71% in the MDMA group vs 48% in placebo lost their diagnosis. The effect persisted for 6 months after the last session.

How does MDMA work in PTSD therapy at the neurochemical level?

MDMA (3,4-methylenedioxymethamphetamine) acts as an entactogen-empatogen, releasing serotonin through the SERT transporter, dopamine, and norepinephrine, and stimulating the release of oxytocin and prolactin. Mithoefer 2011 in the Journal of Psychopharmacology indicates that MDMA reduces amygdala activity by 20-30% and increases medial prefrontal cortex activity, allowing for the processing of traumatic memories without emotional overload (Journal of Psychopharmacology, 2011). This is the so-called therapeutic emotional tolerance window.

What are the key findings of psilocybin research in treatment-resistant depression?

Goodwin 2022 in the New England Journal of Medicine (COMP360, n=233) showed a reduction in the MADRS scale by 12 points after a single dose of 25 mg of psilocybin vs 5.4 points in placebo after 3 weeks, with remission in 29% of patients (NEJM, 2022). Carhart-Harris 2021 in Nature Medicine (n=59) demonstrated that 2 sessions of 25 mg psilocybin were at least equivalent to 6 weeks of escitalopram therapy, with remission in 57% of patients vs 28% in the SSRI group. Davis 2020 in JAMA Psychiatry (Johns Hopkins, n=27) achieved a clinical response in 71% of patients.

What are the most serious risks of psychedelic therapy?

The main risks include: triggering psychosis in individuals with a family or personal history of schizophrenia and bipolar affective disorder (BAD), serotonin syndrome when combined with SSRIs, SNRIs, MAOIs, tramadol, triptans (MAOIs carry a risk of death), a 15-30% increase in blood pressure during sessions, transient anxiety reactions in 30-40% of participants, and rare HPPD. MDMA additionally carries the risk of hyperthermia and hyponatremia. Johnson 2019 in ACS Pharmacology and Translational Science lists seven areas of risk requiring clinical assessment (ACS Pharmacology, 2019).

Which country was the first to register MDMA and psilocybin as medications?

Australia. In February 2023, the Therapeutic Goods Administration (TGA) moved psilocybin and MDMA from Schedule 9 (prohibited) to Schedule 8 (controlled prescription drugs) for the treatment of treatment-resistant depression (psilocybin) and PTSD (MDMA) respectively (TGA, 2023). As of July 1, 2023, authorized psychiatrists can prescribe these substances in the context of structured psychotherapy. The cost of a full MDMA-PTSD cycle in Australia is AUD 25,000-35,000, which limits the practical availability of the program.

Why is the set-setting-integration protocol so important?

Set-setting-integration is a three-phase clinical model developed by Timothy Leary in the 1960s and updated at the Johns Hopkins Center for Psychedelic and Consciousness Research. Set refers to the patient's mental state, setting is a safe clinical environment with two therapists and selected music, and integration involves 2-4 psychotherapy sessions after dosing. Watts 2017 in the Journal of Humanistic Psychology showed that skipping integration significantly increases the risk of symptom relapse within 6 months (Journal of Humanistic Psychology, 2017).

Can individuals treated with SSRIs participate in psychedelic therapy?

Only after discontinuing the medications for 2-6 weeks before the session, under the supervision of a psychiatrist. Chronic SSRIs and SNRIs suppress the psychedelic effect through down-regulation of 5-HT2A receptors, and simultaneous use with psilocybin or MDMA carries the risk of serotonin syndrome. Fluoxetine, with its long half-life, requires a longer washout (4-6 weeks) than sertraline or escitalopram (2-3 weeks). MAOIs are an absolute contraindication: they can trigger hypertensive crises and serotonin syndrome with fatal outcomes.

This article is for educational and informational purposes only and does not constitute medical advice. It does not promote, encourage, or serve as an instruction for the use of MDMA, psilocybin, psilocybin mushrooms, or other legally controlled substances in Poland. MDMA and psilocybin are illegal in Poland according to the Act on Counteracting Drug Addiction from July 29, 2005 (Journal of Laws 2005 No. 179 item 1485, Schedule I-P), and their possession, production, and trade are punishable by up to 10 years in prison. Never use these substances on your own. Psychedelic therapy is conducted only within registered clinical trials or in countries where it has been legally registered (currently Australia). Particular risks apply to individuals with a family or personal history of psychosis, schizophrenia, bipolar affective disorder, as well as those taking SSRIs, SNRIs, or MAOIs (risk of serotonin syndrome, including fatal outcomes with MAOIs). Before making any decisions regarding the treatment of depression, anxiety, PTSD, or addictions, consult a psychiatrist. CBD, CBG, and other supplements do not replace psychiatric treatment.

Author: Michał Waluk, Editor of the Bucha blog
Publication date: April 24, 2026
Last update: April 24, 2026